Tower Research Capital LLC (TRC)
Position in ESLA — Estrella Immunopharma, Inc.
CIK 1533421
NEW YORK, NY
Position in ESLA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,150
+$533 QoQ
Shares Held
4,859
+21.0% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ESLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Tower Research Capital LLC (TRC) holds $64,695,660 across 441 Biotechnology names. ESLA ranks #306 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
12,112 | $8,844,787 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
13,904 | $6,208,692 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,378 | $3,382,617 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,627 | $3,185,285 | |
| 5 | INSM |
INSMED Inc
|
15,410 | $2,519,843 | |
| 6 | LKFT |
Lakefront Biotherapeutics NV
|
66,536 | $1,996,080 | |
| 7 | MRNA |
Moderna, Inc.
|
33,728 | $1,713,382 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
14,349 | $1,065,556 |
All Filings in ESLA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,150 | 4,859 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $4,617 | 4,015 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $4,409 | 4,593 | Shares | Defined | 2025-08-15 | |
| 2025-03-31 | $5,233 | 5,646 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $4,545 | 3,788 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $6,644 | 5,728 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $7,508 | 7,151 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $6,908 | 5,571 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $701 | 632 | Shares | Defined | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||